CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- 4 Open-market sale Chief Financial Officer sold 3,083 shares at an average $54.05 ($166,641)
- 4 Open-market sale President & CEO sold 26,794 shares at an average $54.03 ($1,447,679)
- 4 Open-market sale Chief Operating Officer sold 8,420 shares at an average $59.24 ($498,784)
- 4 Open-market sale President & CEO sold 26,794 shares at an average $59.32 ($1,589,506)
- 4 Open-market sale Chief Financial Officer sold 3,083 shares at an average $59.24 ($182,635)
- 4 Open-market sale Director sold 10,000 shares at an average $59.25 ($592,504)
- 4 Open-market sale Chief Operating Officer sold 3,810 shares at $45.00 ($171,450)
- 4 Open-market sale Director sold 28,369 shares at an average $43.40 ($1,231,238)
- 4 Open-market sale Chief Financial Officer sold 17,107 shares at an average $43.39 ($742,323)
- 4 Open-market sale Chief Operating Officer sold 25,211 shares at an average $43.40 ($1,094,032)
- 4 Open-market sale President & CEO sold 64,562 shares at an average $43.43 ($2,803,800)
- 4 Open-market sale Director sold 12,897 shares at $43.50 ($561,021)
- 4 Open-market sale Chief Operating Officer sold 4,210 shares at an average $43.45 ($182,917)
- 4 Open-market sale Chief Operating Officer sold 4,720 shares at $45.24 ($213,542)
- 4 Open-market sale Chief Operating Officer sold 3,700 shares at $45.07 ($166,747)
- 4 Open-market sale Chief Operating Officer sold 4,210 shares at $41.65 ($175,352)
- 4 Open-market sale President & CEO sold 26,794 shares at an average $41.70 ($1,117,225)
- 4 Open-market sale Director sold 10,000 shares at $41.69 ($416,858)
- 4 Open-market sale Chief Financial Officer sold 3,083 shares at $41.67 ($128,482)
- 4 Grant or award Chief Financial Officer acquired 15,000 shares (grant or award)
Page 10 of 13 · 252 filings